<?xml version="1.0"?>
<Articles JournalTitle="Traditional and Integrative Medicine">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Traditional and Integrative Medicine</JournalTitle>
      <Issn>2476-5104</Issn>
      <Volume>7</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2022</Year>
        <Month>09</Month>
        <Day>05</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Evaluation of the Effect of Alkaloid Berberine on the Positive and Negative Symptoms of the Patients with Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial</title>
    <FirstPage>287</FirstPage>
    <LastPage>293</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Ebrahim</FirstName>
        <LastName>Moghimi Sarani</LastName>
        <affiliation locale="en_US">Department of Psychiatric, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Fatemeh</FirstName>
        <LastName>Ghorbannezhad</LastName>
        <affiliation locale="en_US">Department of Psychiatric, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad Hassan</FirstName>
        <LastName>Meshkibaf</LastName>
        <affiliation locale="en_US">Department of Clinical Biochemistry, Fasa University of Medical Sciences, Fasa, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Marjan</FirstName>
        <LastName>Shakibaee</LastName>
        <affiliation locale="en_US">Department of Clinical Biochemistry, Fasa University of Medical Sciences, Fasa, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Seyed Hamdollah</FirstName>
        <LastName>Mosavat</LastName>
        <affiliation locale="en_US">Research Center for Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2021</Year>
        <Month>12</Month>
        <Day>02</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2022</Year>
        <Month>05</Month>
        <Day>07</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Schizophrenia is a severe psychiatric condition that affects approximately 1% of the global population. Over the last decade, the efficacy of berberine as a complementary therapy in psychiatric diseases without significant side effects has been demonstrated. Therefore, this study assessed&#xA0;the effect of alkaloid berberine on the positive and negative symptoms in patients with schizophrenia. From December 2020 to March 2021, a total of 86 patients with schizophrenia who were referred to Shiraz Ebne Sina Hospital in South of Iran were divided into two groups; 42 patients with schizophrenia in the placebo group received risperidone at a dosage of 4-6 mg per day, and 44 patients in the treatment group, in addition to risperidone, received berberine at a dosage of 500 mg per day. This treatment regimen was followed for 30 days. The Positive and Negative Syndrome Scale (PANSS) was used to assess the patients&#x2019; symptoms. According to data analysis, The PANSS score in both groups showed a statistically significant decrease after 30 days (p &lt; 0.05); however, this decreasing trend was not statistically significant between the groups (p &gt; 0.05). The current study showed that complementary use of alkaloid berberine capsule with a dose of 500 mg per day did not show better outcomes compared with the placebo in patients with schizophrenia.</abstract>
    <web_url>https://jtim.tums.ac.ir/index.php/jtim/article/view/597</web_url>
  </Article>
</Articles>
